Emerging Pharma Markets: Adapt, Diversify, and Persist
Executive Summary
Emerging global markets are a hot topic in pharmaceutical circles these days, but until recently, most Westerners viewed them as a homogenous cluster. Few executives at corporate headquarters drew distinctions among the various countries, let alone the domestic and international players in those markets. As big pharma bumps up against growth constraints in its traditional markets, however, interest in the "rest of the world" is perking up. The largest pharmaceutical companies are all looking at the same promising half dozen or so emerging countries, but they are taking radically different approaches to tackling them and are moving at different paces.
You may also be interested in...
Bristol Tries Out New Selling Strategy With Yervoy Launch
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
AZ Taps India's Torrent to Add Branded Generics in Emerging Markets
LONDON - To extend its reach in emerging markets, AstraZeneca PLC today said it had signed an agreement with India's Torrent Pharmaceuticals Ltd. for the rights to sell 18 undisclosed generic drugs in nine territories
AZ Taps India's Torrent to Add Branded Generics in Emerging Markets
Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.